Company Filing History:

15 out of 637

Bristol-myers Company

patents

3 out of 3,681

Bristol-myers Squibb Compnay

patents

1 out of 68

Basilea Pharmaceutica Ag

patents

Years Active: 1982-2002

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6489440 - Cyclic compounds (2002-12-03),

2. 5541181 - Compound produced by a strain of micromonospora (1996-07-30),

3. 5208364 - Antibiotic 5-lipoxygenase inhibitors (1993-05-04),

4. 5116845 - BU-3420T antitumor antibiotic (1992-05-26),

5. 5089522 - Antitumor antibiotic BU-3285T (1992-02-18),

6. 5036008 - Antitumor antibiotic BU-3285T (1991-07-30),

7. 4952709 - Antitumor antibiotic BU-3285T compounds (1990-08-28),

8. 4952572 - BU-3420T antifungal antibiotic (1990-08-28),

9. 4916065 - BU-3420T Antitumor antibiotic (1990-04-10),

10. 4868117 - BBM-1675, a new antitumor antibiotic complex (1989-09-19),

11. 4803224 - Antiviral antibiotic complex (1989-02-07),

12. 4780416 - Microorganism for BBM 928 production (1988-10-25),

13. 4708872 - Antitumor antibiotic complex (1987-11-24),

14. 4675187 - BBM-1675, a new antibiotic complex (1987-06-23),

15. 4631256 - Fermentation process for BBM-928 (1986-12-23),

Title: The Innovative Contributions of Hiroaki Ohkuma: Patents and Collaborations

Introduction: Hiroaki Ohkuma, based in Tokyo, Japan, is a prominent inventor with a remarkable portfolio of 19 patents. His work primarily focuses on the development of novel compounds with significant therapeutic potential. Ohkuma's innovations reflect his commitment to advancing medical science.

Latest Patents: One of Ohkuma's latest patents includes cyclic compounds, specifically a novel compound known as BU-4664L. This groundbreaking compound is produced through the fermentation of Micromonospora sp. M990-6 and possesses noteworthy anti-inflammatory and anti-tumor cell activities. The uniqueness of BU-4664L lies in its structure, which illustrates the sophistication of Ohkuma's research and development efforts.

Career Highlights: Over the years, Hiroaki Ohkuma has contributed his expertise to reputable companies, including Bristol-Myers Company and Bristol-Myers Squibb Company. His involvement in these organizations has played a critical role in the progression of various pharmaceutical projects, emphasizing his impact on the field of medicine.

Collaborations: Ohkuma has collaborated with notable professionals in the industry, including Masataka Konishi and Hiroshi Kawaguchi. These partnerships showcase the collective effort required to drive innovation in developing life-changing medical treatments.

Conclusion: Hiroaki Ohkuma's dedication to innovation through his extensive patent portfolio and collaborative efforts underscores his significance in the realm of medicinal chemistry. As he continues to explore new horizons, Ohkuma's work will undoubtedly benefit the medical community and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.